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have been reported, their relevance to human skin cancer remains unknown. In this report, we
analyzed gene expression profiles of paired specimens of keratinocyte carcinomas with their
matched normal skin tissues as the control. Among several novel findings, we discovered a sig-
nificant number of zinc finger encoding genes up-regulated in human BCC. In BCC, a novel link
was found between hedgehog signaling, Wnt signaling, and the cilium. While the SCC cancer-
stem-cell gene signature is shared between human and mouse SCCs, the hair follicle stem-cell
signature of mice was not highly represented in human SCC. Differential gene expression (DEG)
in human BCC shares gene signature with both bulge and epidermal stem cells. We have also
determined that human BCCs and SCCs have distinct gene expression patterns, and some of
them are not fully reflected in current mouse models.
Copyright ª 2019, Chongqing Medical University. Production and hosting by Elsevier B.V. This is
an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/
by-nc-nd/4.0/).Introduction
Keratinocyte carcinomas, which encompass cutaneous
squamous cell carcinoma (SCC) and basal cell carcinoma
(BCC), are the most common malignancies in Caucasians,
with continually increasing incidence worldwide.1 UV irra-
diation via excessive sun exposure is the most significant
risk factor for both SCC2,3 and BCC,4,5 and most gene mu-
tations have UV signatures. Additionally, organ trans-
plantation patients have a significantly higher incidence of
SCC (>100 times than the general population) and an
elevated incidence of BCC (>10 times more than the gen-
eral population).6e8 Although SCC and BCC both originate
from keratinocytes, they are very distinct in several as-
pects. While BCC is known to be caused by uncontrolled
activated hedgehog signaling, SCC has alterations in many
genes, including Notch gene families, RAS and its down-
stream effectors, and Cyclin-Dependent Kinase Inhibitor 2A
(CDKN2A). Mutations of TP53 are found in both BCC and
SCC, and those mutations show an UV irradiation
signature.8,9
The link between hedgehog signaling and BCC came
from studies of a rare genetic disorder of the skin, basal
cell nevus syndrome, initially through genetic linkage
analysis followed by direct mutation analysis of gene
Patched 1 (PTCH1).10,11 Further studies revealed frequent
mutations of the hedgehog signaling molecules in spo-
radic BCC, including PTCH1 and Smoothened (SMO).12e14
Inactivated mutations of the hedgehog ligand-receptor,
PTCH1, or gain-of-function mutations of SMO all lead to
constitutive activation of the hedgehog pathway.
Currently, two SMO antagonists, vismodegib15e17 and
sonidegib,18e20 have been approved to treat locally
advanced and metastatic BCCs. Despite the fact that
almost all BCCs have activated hedgehog signaling
through gene mutations of PTCH1 and SMO, less than 40%
of tumors in sporadic BCCs are responsive to SMO an-
tagonists, and the underlying mechanisms are currently
unknown. It is hoped that the transcriptome of BCC may
reveal why some BCCs are quite responsive to SMO an-
tagonists while others are nonresponsive.
In contrast to BCC, treatment of SCC with chemotherapy
or radiation often yields low and unsatisfactory responses.al., Distinct transcriptomic lands
doi.org/10.1016/j.gendis.2019.10There are several clinical trials with promising results in
SCC,21e24 including EGFR inhibitor-based trials and immune
therapy using PD-1 or PD-L1 antibodies. One major chal-
lenge for such trials is identifying the right patient popu-
lation. Further analyses of gene expression profiling in
individual SCC tumors may identify biomarkers for SCC
treatment.
Thus, transcriptome data on BCC and SCC are currently
badly needed, both for understanding the biology of kera-
tinocyte carcinomas and for designing strategies for
effective treatment. While several groups have reported
gene expression profiles of human BCCs and SCCs, only a
few studies have compared gene expression between
cancerous skin specimens and corresponding adjacent
normal skin using microarray technology.25e29 To our
knowledge, no RNA-seq data were generated from non-
melanoma skin tumors and the matched adjacent normal
specimens in The Cancer Genome Atlas (TCGA) database. A
previous systematic comparison of several microarray-
based gene expression analyses did not reveal consensus
genes, and individual differences contributed significantly
to this issue.30 In addition, tumor contents vary signifi-
cantly. Comparing the transcriptome data of BCC and SCC
will enable us to understand the differences and the simi-
larities between BCCs and SCCs.
Several mouse models have been generated to study skin
stem cell biology and the cancer biology of SCC and BCC.
While these model systems provide an insightful under-
standing of skin cancer biology, the relevance of these
studies to human tumors is currently unclear. Genetic
lineage tracing in the mouse model has generated a wealth
of information about the specific subpopulations of cells
that contribute to tissue homeostasis and cancer, particu-
larly in intestine, skin, and bone marrow.31e37 In the skin,
there are several stem cell pools, including hair follicle
bulge and inter-follicular epidermal stem cells. It is pro-
posed that BCC preferentially arises from stem cells
within a hair follicle or a region within the inter-follicular
epidermis called touch dome epithelia.5,38e40 As pre-
dicted from the mouse models, squamous cell carcinomas
(SCCs), on the other hand, can arise from inter-follicular
epidermal stem cells, hair follicle stem cells, or
both.41e43 Currently, it is not known whether the genecapes of cutaneous basal cell carcinomas and squamous cell car-
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sponding human tumor type.
In this study, we analyzed the transcriptomes of 25
paired BCCs and 10 paired SCCs. Through comparison of
tumor tissues with the adjacent normal skin tissues, we
identified tumor-specific gene expression alterations as
well as signaling networks in BCC and SCC. We also
compared BCC with SCC by their genome-wide tran-
scriptome patterns and corresponding biological functions.
Furthermore, we assessed the enrichment of gene expres-
sion signatures from mouse models in human cancer
specimens.
Materials and methods
Human specimens and tissue processing
The Institutional Review Board approved this study at
Indiana University School of Medicine, Indianapolis, IN.
Each patient provided written informed consent. Skin
specimens (cancerous and adjacent normal skin tissues)
were collected in the operating room, quick-frozen in
liquid nitrogen, and stored in an 80゜C freezer. For tissue
processing, each specimen was divided into three por-
tions: one for haemotoxylin and eosin (H&E) staining, one
for RNA extraction, and one for backup. The portion for
H&E staining was first fixed in formalin for 24 h, then
processed for paraffin embedding in a Leica TP1020 tissue
processor. Paraffin-embedded tissues were sectioned at
5 mm for H&E staining, which was used to determine the
tumor contents in the specimens using Image J software,
and only tumor tissues with high tumor content (>30% of
the tissue area as shown in H&E images) proceeded to
gene expression analysis. Matched normal specimens
were collected to contain epidermis (Supplemental
Fig. 1).
RNA extraction
Total RNAs were extracted using TRI@ reagent.44 For tran-
scriptomic analysis, the RNA quality in each specimen was
assured by the Agilent Bioanalyzer profiles before moving
on to cDNA synthesis and library construction (service pro-
vided by the Broad Institute).
RNA-seq analysis
More than 95% of samples had total raw reads over 65
million (see Supplemental Table 1 for details). The raw
sequencing data were processed with one of the most
popular RNA-seq workflows, Tophat-HTSeq. The sequencing
reads were aligned to the human genome (hg19) by
Tophat.45 The mean percentage of mapped reads reached
about 81%, with an average of 51 million reads aligned in
pairs. We then used HTSeq-count46 to summarize transcript
counts from uniquely mapped reads based on the reference
transcriptome profile (Homo_sapiens.GRCh37.73.gtf). The
gene-level counts were transformed by a base-2 logarithmic
scale on read counts per million (CPM) for normalization.
Those genes with average CPM less than 1.0 for all fourPlease cite this article as: Wan J et al., Distinct transcriptomic lands
cinomas, Genes & Diseases, https://doi.org/10.1016/j.gendis.2019.10groups of samples, BCC normal/tumor, and SCC normal/
tumor, were removed from the differentiation analysis. The
paired t-test was performed between tumors and matched
normal specimens for BCC and SCC. All p-values were
modified by multiple testing correction via a false discovery
rate (FDR) estimation. Differentially expressed genes
(DEGs) were identified according to the cutoffs chosen, |
log2FC| > 1 and FDR < 0.01 for BCC, or |log2FC| > 1 and
FDR < 0.05 for SCC.
Real-time PCR
Real-time quantitative PCR analyses were performed ac-
cording to a previously published procedure.47 The CT
values were analyzed in Microsoft Excel using the compar-
ative CT (DDCT) method as described by the manufacturer
(Applied Biosystems, Foster City, CA). The amount of target
(2DDCT) in the tumor was calculated by normalization to an
endogenous reference (Gapdh for mice and GAPDH for
humans), and relative to the value of the adjacent normal
skin specimen. All TaqMan primers and probes were pur-
chased from Applied Biosystems Inc. For each target gene,
four pairs of tumors, either BCC or SCC, and matched
adjacent normal skin were used for gene expression ana-
lyses to validate the RNA-sequencing data.
GO and KEGG pathway analysis
The webserver, DAVID Bioinformatics Resources 6.8
(https://david.ncifcrf.gov/home.jsp), was used for GO and
KEGG pathway analysis. We compared the occurrences of
GO terms and KEGG pathways in the foreground gene, e.
g., DEG up-regulated in BCCs, to the background, e.g., all
expressed genes in our RNA-seq dataset. The significantly
over-represented GO terms and KEGG pathways were
determined by the cutoff of FDR-adjusted p < 0.05.
Statistical enrichment analysis
The statistical significance of an overlap between two gene
sets was evaluated by the fold enrichment (F.E.) and the p-
value. p-value was calculated based on a hypergeometric
model.
Results
Identification of differentially expressed genes
(DEGs) in BCC and SCC
We selected 35 paired specimens, with tumor samples and
the adjacent normal skin tissues, from 126 skin cancer pa-
tients of the Indiana University Dermatology Clinics. The
rationale for selecting patient samples instead of using all
specimens is two-fold. First, we want to reduce individual
differences among patients, for which we performed a
paired comparison between each tumor specimen and the
surrounding matched normal skin. Second, because we
want to reduce the noise of gene expression from non-
cancerous cells, we used ImageJ analyses of H&E images to
determine the tumor contents in the specimens (seecapes of cutaneous basal cell carcinomas and squamous cell car-
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matched normal skin, or the adjacent skin tissue has cancer
cells from the study. We anticipate that if tumor content is
less than 30%, the influence of non-cancerous cells will be
significant. Only specimens with tumor content >30% were
used for further analyses. As shown in Supplemental Fig. 1,
all skin specimens included epidermis and dermis. The
normal tissue was the skin tissue adjacent to the tumor but
without any tumor cells (as assessed by H&E staining).
These 35 paired human tumor specimens included 25 paired
BCCs and 10 paired SCCs. RNA-seq technology was adopted
to examine the gene expression profiles of all 70 specimens.
First, we performed several quality-control analyses on
RNA-seq data of 35 pairs of specimens. Principal component
analysis (PCA) was used to evaluate the relationship be-
tween these 70 samples (Fig. 1A). The first three principal
components (PCs) together explain about 91% of the total
variance. The PCA plots (Fig. 1A) show substantial similarity
between most normal samples, regardless of whether they
were gathered from BCC or SCC patients. Significant dif-
ferences between tumor and normal samples were
observed in the comparisons of PC1 and PC2, or PC1 and
PC3.
Furthermore, notable disparities between SCC and BCC
in the human tumor specimens confirm that gene expres-
sion profiles differ between the two cancer types. Such
differences were also reflected by the correlations on the
fold-change (FC) of tumor vs. normal among 35 patients.
Higher correlation coefficients were observed within either
the BCC or the SCC group, whereas the correlations across
BCC and SCC were lower (Supplemental Fig. 2). These re-
sults also indicate the high quality of our RNA-seq data.
Next, differential expression was analyzed by paired
comparison between normal and tumor specimens (either
SCC or BCC), regardless of gender identity alongside other
patient information. Differentially expressed genes (DEGs)
were identified based on defined cutoff values. For BCC, if
one gene had an amplitude of fold change (FC) larger than 1
(in log scale with base 2, corresponding to linear 2-fold) and
p-value less than 0.01 after multiple test correction via
False Discovery Rate (FDR) estimation, the gene was iden-
tified as DEG (Fig. 1B). Considering the sample size for SCC,
which is only 40% of BCC numbers, we chose cutoffs, |
log2FC| > 1 and FDR-adjusted p-value < 0.05, to mark the
DEGs (Fig. 1C). In summary, we found 1884 up-regulated
and 1106 down-regulated genes in BCC tumors in compari-
son with matched normal specimens (Fig. 1B and
Supplemental Table 2). In SCC tumors, on the other hand,
we found 601 up-regulated and 1382 down-regulated DEGs
(Fig. 1C and Supplemental Table 2). Several genes of in-
terest, some of which are implicated in the Wnt or the
hedgehog signaling pathway, were selected to validate
gene expression for both BCC and SCC by analysis of real-
time PCR results (Fig. 1D). For example, Secreted Frizzled
Related Protein 5 (SFRP5) is a protein involved in the Wnt
signaling pathway that was highly expressed in BCC tumors,
as shown in both RNA-seq and real-time PCR (Fig. 1D).
Similarly, the pattern of hedgehog-signaling target gene
expression (e.g., PTCH1) indicates elevated hedgehog
signaling in BCC. GLI Family Zinc Finger 1 (GLI1), a critical
transcription factor (TF) in hedgehog signaling, was signif-
icantly up-regulated in BCC (Fig. 1D). Elevated genePlease cite this article as: Wan J et al., Distinct transcriptomic lands
cinomas, Genes & Diseases, https://doi.org/10.1016/j.gendis.2019.10expression in BCC tumor was also observed on cilium as-
sembly genes, such as ciliary Dynein Axonemal Heavy Chain
14 (DNAH14), associated with microtubule motor activity
and G Protein-Coupled Receptor 161 (GPR161) (Fig. 1D). In
SCC, elevated expression of Aurora Kinase A (AURKA),
which is involved in the cell cycle,48 was observed (Fig. 1E).
These gene expression changes were further confirmed by
real-time PCR (Fig. 1D and E).
One significant discovery in our analysis is the elevated
expression of a significant number of C2H2-type Zinc finger
encoding genes. C2H2-type Zinc Finger (ZF) proteins form a
large transcription-factor family across the whole
genome.49 In this study, 628 out of 16382 expressed genes
(3.8%) belong to C2H2-type ZF (Fig. 2A). Surprisingly, about
one-quarter of C2H2-ZF (168) proteins were found in the
group of 1884 elevated DEGs in BCC tumors. For instance,
GLI1, which contains C2H2-ZF domains, was up-regulated in
BCC (Fig. 1D). The ratio of 8.9% was much higher than its
proportion in all expressed genes (3.8%), reflected by 2.3-
fold enrichment (F.E.) with p-value 3.2  1027 (Fig. 2A
and Supplemental Fig. 3A). When we focused on 156 and
217 up-regulated transcription factors in BCC implicated in
transcription activity associated with sequence-specific
DNA binding (GO:0003700) and regulation of transcription
(GO:0006355) as seen in Fig. 2B, we found that 97 (62.2%,
p Z 1.7  1098) and 148 (68.2%, p Z 1.8  10161) TFs
have C2H2-ZF domains (Supplemental Fig. 3B), indicating a
critical role of C2H2-ZF transcription regulation in BCC. In
contrast, only 16 out of 1106 (1.4%) repressed genes in BCC
have a C2H2-type domain (Supplemental Fig. 3A and 3B).
Significant enrichment of C2H2-type ZF protein was not
observed in neither up- nor down-regulation of SCC
(Supplemental Fig. 3A and 3B), suggesting a BCC-specific
phenotype associated with regulation of these C2H2-ZF
proteins for BCC tumor formation. It is known that C2H2-
type ZF proteins directly bind specific DNA sequences in
the genome, involving skin homeostasis regulation. Struc-
tural analyses indicate that the majority of the C2H2-type
zinc finger molecules up-regulated in BCC contain a KRAB
domain.50 Previous work indicates that KRAB domain pro-
teins are critical for the regulation of embryonic develop-
ment, cell differentiation, and cell cycle regulation. The
exact mechanisms for selective up-regulation of KRAB
domain-containing molecules in BCC are currently
unknown.Novel signaling networks in BCC and SCC
We used DAVID51 to perform functional enrichment analysis
on different groups of DEGs. Several Gene Ontology (GO)
functions and KEGG pathways were found to be directly
associated with the up-regulation of 1884 DEGs in BCC tu-
mors (Fig. 2B). It is not surprising that 19 out of 46 genes
annotated in the pathway of basal cell carcinoma were
activated in our human BCC cohort, including known
hedgehog target genes GLI1, Hedgehog Interacting Protein
(HHIP), and PTCH1. Our analyses also uncovered several
new alterations in BCCs. First, many pathways associated
with transcription activity were up-regulated in BCC tu-
mors, including transcription regulation (GO:0003700 and
GO:0006355, see Fig. 2B). Also, expression of genescapes of cutaneous basal cell carcinomas and squamous cell car-
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Figure 1 Differentially expressed genes (DEGs) identified in human BCC and SCC by comparison between tumor and adjacent
normal skin. (A) shows principal component analysis (PCA) of BCC (PC2, left) and SCC (PC3, right) (including both tumors and
matched adjacent normal skin). (B) and (C) show volcano plots for BCC (B) and SCC (C), where the purple dots represent the DEGs
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GO:0005201, and GO:0022617) and developmental signaling
pathways (has04340, hsa 04310, and GO:0060070) was
elevated in BCC (see Fig. 2B). Many prominent up-regulated
DEGs (Fig. 1B and D) were implicated in the Wnt signaling
pathway, the Hedgehog signaling pathway, and cilium. It is
known that cilium is a critical structure for hedgehog and
Wnt signaling.52,53 For example, cilium is required for signal
transduction from Smoothened to Gli transcription factors,
and lack of cilium prevents hedgehog signaling.54,55 When
examining the connections among these three pathways in
BCC, we found that hedgehog signaling plays a central role
in terms of proteineprotein interaction (PPI) network on
up-regulated DEGs. Hedgehog signaling is connected with
Wnt signaling and cilium components at multiple points,
whereas Wnt signaling has little connection with cilium
components (Fig. 2C). For example, another C2H2-type ZF
protein, GLI Family Zinc Finger 2 (GLI2), involved in
hedgehog signaling, interacts with the Wnt pathway
through PPI with Cyclin D2 (CCND2), while being connected
with other molecules in Cilium, including RPGR Interacting
Protein 1-Like (RPGRIP1L), Kinesin Family Member 7 (KIF7),
IFT family genes. This functional analysis of up-regulated
DEGs in BCC further confirms the existence of the
hedgehog-Wnt signaling network and the significance of
cilium for hedgehog signaling.
Transcriptome comparison between BCC and SCC
Through a paired comparison between BCC and SCC tumors
and normal specimens, we generated a list of DEGs that are
either up-regulated or down-regulated. The different sets
of DEGs may reflect commonalities between BCC and SCC,
or tumor-specific changes and their corresponding biolog-
ical functions. For example, as shown in Fig. 3A, 1106 BCC
down-regulated genes were significantly over-represented
in genes encoding for proteins for keratin filament
(GO:0045095), epithelial morphology (GO:0005615,
GO:0005887, and GO:0005882), keratinocyte differentia-
tion (GO:0045615), hair follicle (GO:0042633), and reduced
lipid metabolism (such as lipid metabolic process
GO:0006629), suggesting reduced cell differentiation in BCC
(see Fig. 3A). In SCC, significantly up-regulated genes
encode proteins for cell division (GO:0051301,
GO:0007062), cell cycle (hsa 04110), spindle organization
(GO:0051233, GO:0000922 and GO0005819), and
microtubule-related biological processing (GO:0000776,
GO:0007059 and GO:0032467) (Fig. 3B). Consistently, genes
associated with negative regulation of cell growth
(GO:0030308), cell adhesion (GO:0007155), RNA polymerase
II core promoter proximal region sequence-specific binding
activity (GO:0001077), or extracellular matrix
(GO:0005576, GO:0031012) were notably suppressed in SCC
(Fig. 3C). This finding is consistent with increased cell
proliferation in SCC.
BCC and SCC had distinct transcriptome patterns in
general (Fig. 4A). The Circos plot56 in Fig. 4A displays the
average FCs between tumors and matched normalup-regulated and blue dots being those down-regulated. (D) and (E
in the left panel) and validated by real-time PCR (brown bars in the
Please cite this article as: Wan J et al., Distinct transcriptomic lands
cinomas, Genes & Diseases, https://doi.org/10.1016/j.gendis.2019.10specimens for BCC (red) and SCC (blue). DEGs identified
from BCC were quite different from those of SCC. However,
we did identify 679 genes as shared DEGs between both BCC
and SCC (Supplemental Fig. 4) regardless of the direction of
gene expression change. Among them, 144 DEGs were
elevated and 360 DEGs were suppressed in both BCC and
SCC (Fig. 4B). These overlaps were statistically significant,
in that they had fold enrichments of 2.1 and 3.9 compared
with random selection, with p Z 1.1  1018 and
2.4  10128, respectively. Only 11 genes were down-
regulated in BCC but up-regulated in SCC. The fold
enrichment was very low, 0.27, with p Z 9.0  109. It thus
appears that there are more overlaps between BCC and SCC
among up-regulated than among down-regulated genes.
We also found distinct functions for genes with similar
expression patterns in both BCC and SCC. For example, we
found that genes up-regulated in both BCC and SCC tumors
tend to be involved in cell division, cell cycle, chromosome
segregation, and cytokinesis regulation, e.g., Cyclin-
Dependent Kinase 1 (CDK1), TTK Protein Kinase (TTK )
(Fig. 4C). In contrast, genes suppressed in both BCC and
SCC, e.g., Peroxisome Proliferator-Activated Receptor
Gamma (PPARG), are associated with metabolism (Fig. 4D).
As expected, some BCC-specific genes, e.g., GLI2, PTCH1/
2, Frizzled Class Receptor 7 (FZD7), were high in BCC but
suppressed in SCC (Fig. 4E). Of the 11 genes down-regulated
in BCC but up-regulated in SCC, six are integral components
of plasma membrane proteins (Fig. 4F), whose roles in the
development of BCC and SCC are not yet understood.
The relevance of mouse model-generated data to
human BCCs and SCCs
Different mouse models of SCC and BCC are widely used for
studying stem cell, cancer stem cell, and cancer bio-
logy.57e66 To determine the relevance of established mouse
models to human skin cancer, we first determined whether
the mouse SCC stem cell (SCC-SC) signature genes are
highly represented in the human SCC.66 We found that 598
mouse SCC-SC genes with human orthologs were expressed
in our human tumor or normal tissues. Of those orthologs,
66 (11.0%) were recognized as up-regulated DEGs in human
SCC specimens (Fig. 5 and Supplemental Table 2). In
contrast, only 3.7% of all 16,382 expressed genes were up-
regulated in SCC (F.E. Z 3.0 and p Z 6.0  1016), indi-
cating that the mouse SCC-SC gene signature was indeed
enriched in human SCCs. Examples of SCC stem cell marker
include Sex Determining Region Y-Box 2 (SOX2), BUB1
Mitotic Checkpoint Serine/Threonine Kinase (BUB1), and
Cyclin E1 (CCNE1). The function of these SCC-SC genes in-
cludes cell division and sister chromatid cohesion. On the
other hand, very few mouse SCC-SC genes were down-
regulated in human SCCs: only 28 (4.7% of) SCC-SC signa-
ture genes were present in 1382 down-regulated SCC DEGs,
which is significantly under-represented (F.E. Z 0.56 and
p Z 1.0  104, Fig. 5). These results suggest that human
SCC does share some cancer-stem-cell gene signature with
its mouse counterpart.) show gene expression profiles achieved by RNA-seq (blue bars
right panel) of several DEG examples for BCC (D) and SCC (E).
capes of cutaneous basal cell carcinomas and squamous cell car-
.004
Figure 2 Up-regulated DEGs in BCC. (A) shows a 3-D pie chart for the ratio of C2H2-ZF proteins in all expressed genes (left) or
DEGs up-regulated in BCC tumor (right). (B) shows top Gene Ontology (GO) terms and KEGG pathways significantly enriched in up-
regulated DEGs in BCC. (C) shows a diagram of proteineprotein interactions (PPIs) of DEGs implicated in the Wnt signaling pathway,
Hedgehog signaling pathway, and Cilium components.
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follicular epidermal stem cell (303 Ep-SC genes) and hair
follicle stem cell (124 HF-SC genes) signatures in human
SCCs. We found that only Ep-SC genes were over-
represented in up-regulated SCC DEGs (F.E. Z 3.3 and
p Z 1.0  1010) (Fig. 5). The functions of these 37Figure 3 Functional enrichment analysis of different sets of D
regulated genes in BCC; B shows pathways from up-regulated gen
in SCC.
Please cite this article as: Wan J et al., Distinct transcriptomic lands
cinomas, Genes & Diseases, https://doi.org/10.1016/j.gendis.2019.10activated Ep-SC genes, e.g., ITGA and LAMA family genes,
include hemidesmosome assembly, ECM-receptor interac-
tion, and focal adhesion. ITGA6 (CD49f) is a known marker
for epidermal stem cells.67 We also noted that Ep-SC and
HF-SC signatures were significantly over-represented in
down-regulated human SCC DEGs (F.E. Z 1.7 and 3.3,EGs. A shows top GO terms and KEGG pathways from down-
es in SCC, and C shows pathways from down-regulated genes
capes of cutaneous basal cell carcinomas and squamous cell car-
.004
Figure 4 Cross-comparison of gene expression profiles between BCC and SCC. (A) shows the Circos plot of average fold change
(FC) between tumor and normal specimens for BCC (red) and SCC (blue), respectively. (B) shows the Venn diagram of numbers of
DEGs in BCC and SCC and the numbers of DEGs that overlap. (CeF) shows selected DEGs and their associated GO functions. (C)
shows up-regulated DEGs in BCC and SCC; (D) shows down-regulated DEGs in both BCC and SCC; (E) shows DEGs up-regulated in BCC
but down-regulated in SCC, and (F) shows DEGs down-regulated in BCC but up-regulated in SCC.
8 J. Wan et al.
+ MODELp Z 1.3  104 and 3.1  1010, respectively). These genes
encode proteins in extracellular space or are associated
with tissue homeostasis.
Finally, we also surveyed the overlap between these
mouse signature genes and DEGs in human BCC specimens.
As expected, the mouse SCC-SC gene signature was not
significantly over-represented in BCC DEGs (Fig. 5 and
Supplemental Table 2). We did notice the co-existence of
both Ep-SC and HF-SC signature genes in the up-regulated
BCC DEGs (F.E. Z 2.1 and 2.4, p Z 2.7  1010 andPlease cite this article as: Wan J et al., Distinct transcriptomic lands
cinomas, Genes & Diseases, https://doi.org/10.1016/j.gendis.2019.106.0  107, respectively). These results are consistent with
previous findings in mouse models that BCCs can arise from
different stem cell pools,38,39,42,58 particularly HF-SC.40
Further KEGG pathway analysis showed that the HF-SC
genes activated in human BCCs were enriched in genes
encoding proteins in the extracellular matrix or involved in
cell adhesion, ECM-receptor interaction, and protein
digestion and absorption. However, 73 Ep-SC genes over-
represented in up-regulated human BCC DEGs encode pro-
teins essential for positive regulation of cell proliferationcapes of cutaneous basal cell carcinomas and squamous cell car-
.004
Figure 5 Presence of mouse signature genes in human BCC/
SCC DEGs. These include signature genes for SCC stem cell
gene signature (SCC-SC), epidermal stem cell gene signature
(Ep-SC), hair-follicle-stem-cell gene signature (HF-SC), and
transient amplifying cell gene signature (TAC). Only significant
(a number marked p < 0.01) overlap were colored by the fold
enrichment (in log scale with base 2 shown at the bottom). The
numeral indicates the number of mouse genes present in
human DEGs.
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PI3K-Akt signaling pathway, the Ras signaling pathway, or
transcriptional dysregulation in cancer, which is consistent
with previous analyses of human BCCs.25 Some of the mouse
HF-SC genes were also enriched in the human BCC down-
regulated DEG group (F.E. Z 2.3 and p Z 4.1  104),
especially HF-SC genes encoding for proteins in the extra-
cellular matrix.
Transit-amplifying cell (TAC) progenitors work during
intermediate stages in tissue regeneration and have been
known to regulate HF morphogenetic growth.68 When we
compared mouse TAC signature with human SCC and BCC
DEGs, 46 out of 160 TAC genes were found significantly
over-represented in suppressed gene sets of human BCC
(F.E.Z 4.3 and pZ 9.2  1018) but not represented in SCC
DEGs. These down-regulated genes encode intermediate
filament proteins, proteins involved in structural molecule
activity, or hair follicle morphogenesis, or were implicated
in the pathway of tight junction, e.g., KRT and CLDN
families.
Taken together, our findings indicate that some mouse
signature genes are highly represented in human tumors,
including elevated expression of SCC SC genes and Ep-SC in
human SCC, as well as up-regulation of Ep-SC, HF-SC, and
TAC genes in human BCC. However, several mouse signature
genes are not represented in human tumors, e.g., the low
representation of HF-SC and TAC genes in human SCC. For
SCC-SC signature genes, not all are up-regulated in humanPlease cite this article as: Wan J et al., Distinct transcriptomic lands
cinomas, Genes & Diseases, https://doi.org/10.1016/j.gendis.2019.10SCC, like the Sox 9 gene. While the exact reasons for the
discrepancies between mouse and human tumors are not
known, we suggest that current mouse models may not
recapture all the features of human tumors, and thus
additional mouse models for BCC and SCC are in greatly
needed for future human relevance studies.
In summary, we have discovered many novel gene
expression features in human BCC and SCC. We discovered
high representation of C2H2-type zinc finger molecules and
several new pathway links in human BCC. We found quite a
few shared genes up-regulated in both BCC and SCC as well
as distinct gene expression signatures in these two tumor
types. Another significant finding in our studies is that many
gene expression signatures in mouse models are not well-
represented in human tumors, such as the low represen-
tation of mouse HF-SC in human SCC. It appears that
development of mouse models for SCC and BCC is necessary
for use in relevance studies.Discussion
Our comparative analyses of the transcriptome profiles of
tumors and matched normal tissues identified many gene
sets representing human BCC and SCC signatures, including
both those reported previously and novel players. Specif-
ically, we discovered a significant number of C2H2-type
Zinc Finger molecules highly represented in human BCC.
While Gli molecules are known downstream transcription
factors for the hedgehog signaling pathway, the exact
function of other zinc finger molecules identified in this
study for stem cells remains to be demonstrated using novel
mouse models.
While our data are consistent with several previously
published results,25,26,28,30 we had several novel findings,
including novel players and signaling networks in BCC.
There are many possible reasons that we uncovered these
new features of BCC and SCC. First, we used matched
tumor-normal tissues to identify tumor-specific gene
expression, which reduced individual differences observed
using random normal skin tissues. Second, we selected
tissues with high tumor contents (>30% by H&E) to reduce
the influence of gene expression from normal cells.
We performed a comprehensive comparison among
human BCC DEGs, SCC DEGs, and mouse skin signature
genes, e.g., mouse SCC-SC, Ep-SC, HF-SC, and TAC, in order
to identify shared and distinct gene signatures between
mouse and human models. Our results detected a sub-
stantial quantity of mouse SCC-SC signature69 in human
SCC, indicating the similarity of cancer-stem-cell gene
signatures between human SCC and mouse SCC. This rele-
vance suggests that mouse models of SCC stem cell biology
may help us understand human SCCs. Meanwhile, many
well-studied mouse skin SCC stem cell genes were not
differentially expressed in the human skin SCC specimens.
We noticed that not all cancer stem cell markers generated
in mouse models were highly expressed in the human SCCs.
For example, CD44 is a cancer stem cell marker for SCC in
the mouse model that was not highly expressed in human
SCC. We suspect that this finding may explain the failed
clinical trial with the CD44 antibody bivatuzumab in
SCC,70,71 as human SCC does not have a high level of CD44.capes of cutaneous basal cell carcinomas and squamous cell car-
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+ MODELA substantial portion of Ep-SC signature genes generated
in the mouse model (but not HF-SC signature genes), were
highly represented in human SCC. Our data are consistent
with the general conclusion from a recent publication that
epidermal stem cells, not HF-SC, give rise to SCCs.72 In BCC,
on the other hand, both Ep-SC and HF-SC gene signatures of
mice were enriched in human BCC. We also noticed that
many HF-SC genes for metabolism, BMP, and Jak-STAT3
signaling were not enriched in human BCC. These results
indicate that cancer cells are not merely an expansion of
tissue stem cells. Instead, cancer cells have undergone
significant alterations in metabolism and signaling. For
example, BMP2 is known to be important for regulation of
proliferation and differentiation in the hair follicle stem
cells,68 and high levels of BMP2 promote cell differentia-
tion.73 In human BCC, BMP2 expression was not significantly
altered, suggesting that BMP regulatory mechanisms may
be hijacked in the cancer cells.
Data availability
Both raw and analyzed data of RNA-seq have been depos-
ited in the GEO database with the accession number
GSE125285. The list of DEGs is available as Supplemental
Table 2 in the paper.Declaration of Competing Interest
The authors state no conflict of interest.
Acknowledgments
This research is generously supported by Riley Children’s
Foundation (J.X.) and AGA Foundation (J.X.). We
acknowledge support from the IU Simon Cancer Center
(Grant P30CA082709), the Purdue University Center for
Cancer Research (Grant P30CA023168), and the Walther
Cancer Foundation.
Appendix A. Supplementary data
Supplementary data to this article can be found online at
https://doi.org/10.1016/j.gendis.2019.10.004.
References
1. Nehal KS, Bichakjian CK. Update on keratinocyte carcinomas. N
Engl J Med. 2018;379(4):363e374.
2. Johnson TM, Rowe DE, Nelson BR, Swanson NA. Squamous cell
carcinoma of the skin (excluding lip and oral mucosa). J Am
Acad Dermatol. 1992;26(3 Pt 2):467e484.
3. Green AC, McBride P. Squamous cell carcinoma of the skin
(non-metastatic). BMJ Clin Evid. 2014;2014.
4. Makarova A, Wang G, Dolorito JA, Kc S, Libove E, Epstein Jr EH.
Vitamin D3 produced by skin exposure to UVR inhibits murine
basal cell carcinoma carcinogenesis. J Investig Dermatol. 2017;
137(12):2613e2619.
5. Epstein Jr EH. Skin cancer: basal cell carcinoma–pay your
money, take your choice. Nat Rev Clin Oncol. 2013;10(9):
489e490.Please cite this article as: Wan J et al., Distinct transcriptomic lands
cinomas, Genes & Diseases, https://doi.org/10.1016/j.gendis.2019.106. Wells 3rd JL, Shirai K. Systemic therapy for squamous cell
carcinoma of the skin in organ transplant recipients. Am J Clin
Oncol. 2012;35(5):498e503.
7. Perez HC, Benavides X, Perez JS, et al. Basic aspects of the
pathogenesis and prevention of non-melanoma skin cancer in
solid organ transplant recipients: a review. Int J Dermatol.
2017;56(4):370e378.
8. Hussein MR. Ultraviolet radiation and skin cancer: molecular
mechanisms. J Cutan Pathol. 2005;32(3):191e205.
9. Jayaraman SS, Rayhan DJ, Hazany S, Kolodney MS. Mutational
landscape of basal cell carcinomas by whole-exome
sequencing. J Investig Dermatol. 2014;134(1):213e220.
10. Johnson RL, Rothman AL, Xie J, et al. Human homolog of
patched, a candidate gene for the basal cell nevus syndrome.
Science. 1996;272(5268):1668e1671.
11. Hahn H, Wicking C, Zaphiropoulous PG, et al. Mutations of the
human homolog of Drosophila patched in the nevoid basal cell
carcinoma syndrome. Cell. 1996;85(6):841e851.
12. Hahn H, Christiansen J, Wicking C, et al. A mammalian patched
homolog is expressed in target tissues of sonic hedgehog and
maps to a region associated with developmental abnormalities.
J Biol Chem. 1996;271(21):12125e12128.
13. Gailani MR, Stahle-Backdahl M, Leffell DJ, et al. The role of the
human homologue of Drosophila patched in sporadic basal cell
carcinomas. Nat Genet. 1996;14(1):78e81.
14. Aszterbaum M, Rothman A, Johnson RL, et al. Identification of
mutations in the human PATCHED gene in sporadic basal cell
carcinomas and in patients with the basal cell nevus syndrome.
J Investig Dermatol. 1998;110(6):885e888.
15. Sekulic A, Migden MR, Oro AE, et al. Efficacy and safety of
vismodegib in advanced basal-cell carcinoma. N Engl J Med.
2012;366(23):2171e2179.
16. Sekulic A, Migden MR, Basset-Seguin N, et al. Long-term safety
and efficacy of vismodegib in patients with advanced basal cell
carcinoma: final update of the pivotal ERIVANCE BCC study.
BMC Cancer. 2017;17(1):332.
17. Sekulic A, Migden MR, Lewis K, et al. Pivotal ERIVANCE basal
cell carcinoma (BCC) study: 12-month update of efficacy and
safety of vismodegib in advanced BCC. J Am Acad Dermatol.
2015;72(6):1021e1026. e1028.
18. Migden MR, Guminski A, Gutzmer R, et al. Treatment with two
different doses of sonidegib in patients with locally advanced
or metastatic basal cell carcinoma (BOLT): a multicentre,
randomised, double-blind phase 2 trial. Lancet Oncol. 2015;
16(6):716e728.
19. Lear JT, Migden MR, Lewis KD, et al. Long-term efficacy and
safety of sonidegib in patients with locally advanced and
metastatic basal cell carcinoma: 30-month analysis of the
randomized phase 2 BOLT study. J Eur Acad Dermatol Vene-
reol. 2018;32(3):372e381.
20. Dummer R, Guminski A, Gutzmer R, et al. The 12-month
analysis from Basal Cell Carcinoma Outcomes with LDE225
Treatment (BOLT): a phase II, randomized, double-blind study
of sonidegib in patients with advanced basal cell carcinoma. J
Am Acad Dermatol. 2016;75(1):113e125 e115.
21. Magrini SM, Buglione M, Corvo R, et al. Cetuximab and radio-
therapy versus cisplatin and radiotherapy for locally advanced
head and neck cancer: a randomized phase II trial. J Clin
Oncol. 2016;34(5):427e435.
22. Cunningham TJ, Tabacchi M, Eliane JP, et al. Randomized trial
of calcipotriol combined with 5-fluorouracil for skin cancer
precursor immunotherapy. J Clin Investig. 2017;127(1):
106e116.
23. Stevenson ML, Wang CQ, Abikhair M, et al. Expression
of programmed cell death ligand in cutaneous squamous
cell carcinoma and treatment of locally advanced disease
with pembrolizumab. JAMA Dermatol. 2017;153(4):
299e303.capes of cutaneous basal cell carcinomas and squamous cell car-
.004
Transcriptomic landscapes of keratinocyte carcinomas 11
+ MODEL24. Migden MR, Rischin D, Schmults CD, et al. PD-1 blockade with
cemiplimab in advanced cutaneous squamous-cell carcinoma.
N Engl J Med. 2018;379(4):341e351.
25. Bonilla X, Parmentier L, King B, et al. Genomic analysis iden-
tifies new drivers and progression pathways in skin basal cell
carcinoma. Nat Genet. 2016;48(4):398e406.
26. Chitsazzadeh V, Coarfa C, Drummond JA, et al. Cross-species
identification of genomic drivers of squamous cell carcinoma
development across preneoplastic intermediates. Nat Com-
mun. 2016;7:12601.
27. Asplund A, Gry Bjorklund M, Sundquist C, et al. Expression
profiling of microdissected cell populations selected from basal
cells in normal epidermis and basal cell carcinoma. Br J Der-
matol. 2008;158(3):527e538.
28. Jee BA, Lim H, Kwon SM, et al. Molecular classification of basal
cell carcinoma of skin by gene expression profiling. Mol Car-
cinog. 2015;54(12):1605e1612.
29. Wenzel J, Tomiuk S, Zahn S, et al. Transcriptional profiling
identifies an interferon-associated host immune response in
invasive squamous cell carcinoma of the skin. Int J Cancer.
2008;123(11):2605e2615.
30. Van Haren R, Feldman D, Sinha AA. Systematic comparison of
nonmelanoma skin cancer microarray datasets reveals lack of
consensus genes. Br J Dermatol. 2009;161(6):1278e1287.
31. Tumbar T, Guasch G, Greco V, et al. Defining the epithelial
stem cell niche in skin. Science. 2004;303(5656):359e363.
32. Kretzschmar K, Watt FM. Markers of epidermal stem cell sub-
populations in adult mammalian skin. Cold Spring Harb Per-
spect Med. 2014;4(10).
33. Watt FM. Stem cell fate and patterning in mammalian
epidermis. Curr Opin Genet Dev. 2001;11(4):410e417.
34. Morris RJ, Liu Y, Marles L, et al. Capturing and profiling adult
hair follicle stem cells. Nat Biotechnol. 2004;22(4):411e417.
35. Clevers H. Searching for adult stem cells in the intestine. EMBO
Mol Med. 2009;1(5):255e259.
36. Weissman IL. The E. Donnall Thomas lecture: normal and
neoplastic stem cells. Biol Blood Marrow Transplant. 2008;
14(8):849e858.
37. Lapidot T, Sirard C, Vormoor J, et al. A cell initiating human
acute myeloid leukaemia after transplantation into SCID mice.
Nature. 1994;367(6464):645e648.
38. Grachtchouk M, Pero J, Yang SH, et al. Basal cell carcinomas in
mice arise from hair follicle stem cells and multiple epithelial
progenitor populations. J Clin Investig. 2011;121(5):
1768e1781.
39. Wang GY, Wang J, Mancianti ML, Epstein Jr EH. Basal cell
carcinomas arise from hair follicle stem cells in Ptch1(þ/-)
mice. Cancer Cell. 2011;19(1):114e124.
40. Peterson SC, Eberl M, Vagnozzi AN, et al. Basal cell carcinoma
preferentially arises from stem cells within hair follicle and
mechanosensory niches. Cell Stem Cell. 2015;16(4):400e412.
41. Lapouge G, Youssef KK, Vokaer B, et al. Identifying the cellular
origin of squamous skin tumors. Proc Natl Acad Sci U S A. 2011;
108(18):7431e7436.
42. Blanpain C. Tracing the cellular origin of cancer. Nat Cell Biol.
2013;15(2):126e134.
43. Ge Y, Gomez NC, Adam RC, et al. Stem cell lineage infidelity
drives wound repair and cancer. Cell. 2017;169(4):636e650.
e614.
44. Fan Q, Gu D, Liu H, et al. Defective TGF-beta signaling in bone
marrow-derived cells prevents hedgehog-induced skin tumors.
Cancer Res. 2014;74(2):471e483.
45. Trapnell C, Pachter L, Salzberg SL. TopHat: discovering splice
junctions with RNA-Seq. Bioinformatics. 2009;25(9):
1105e1111.
46. Anders S, Pyl PT, Huber W. HTSeq–a Python framework to work
with high-throughput sequencing data. Bioinformatics. 2015;
31(2):166e169.Please cite this article as: Wan J et al., Distinct transcriptomic lands
cinomas, Genes & Diseases, https://doi.org/10.1016/j.gendis.2019.1047. Gu D, Liu H, Su GH, et al. Combining hedgehog signaling inhi-
bition with focal irradiation on reduction of pancreatic cancer
metastasis. Mol Cancer Ther. 2013;12(6):1038e1048.
48. Nikonova AS, Astsaturov I, Serebriiskii IG, Dunbrack Jr RL,
Golemis EA. Aurora A kinase (AURKA) in normal and patholog-
ical cell division. Cell Mol Life Sci. 2013;70(4):661e687.
49. Razin SV, Borunova VV, Maksimenko OG, Kantidze OL. Cys2His2
zinc finger protein family: classification, functions, and major
members. Biochemistry (Mosc). 2012;77(3):217e226.
50. Mackeh R, Marr AK, Fadda A, Kino T. C2H2-Type zinc finger
proteins: evolutionarily old and new partners of the nuclear
hormone receptors. Nucl Recept Signal. 2018;15,
1550762918801071.
51. Huang da W, Sherman BT, Lempicki RA. Systematic and inte-
grative analysis of large gene lists using DAVID bioinformatics
resources. Nat Protoc. 2009;4(1):44e57.
52. Singla V, Reiter JF. The primary cilium as the cell’s antenna:
signaling at a sensory organelle. Science. 2006;313(5787):
629e633.
53. Balmer S, Dussert A, Collu GM, Benitez E, Iomini C, Mlodzik M.
Components of intraflagellar transport complex a function
independently of the cilium to regulate canonical Wnt signaling
in Drosophila. Dev Cell. 2015;34(6):705e718.
54. Schneider L, Clement CA, Teilmann SC, et al. PDGFRalphaalpha
signaling is regulated through the primary cilium in fibroblasts.
Curr Biol. 2005;15(20):1861e1866.
55. Corbit KC, Aanstad P, Singla V, Norman AR, Stainier DY,
Reiter JF. Vertebrate Smoothened functions at the primary
cilium. Nature. 2005;437(7061):1018e1021.
56. Krzywinski M, Schein J, Birol I, et al. Circos: an information
aesthetic for comparative genomics. Genome Res. 2009;19(9):
1639e1645.
57. Nitzki F, Becker M, Frommhold A, Schulz-Schaeffer W, Hahn H.
Patched knockout mouse models of Basal cell carcinoma. J skin
Canc. 2012;2012:907543.
58. Youssef KK, Van Keymeulen A, Lapouge G, et al. Identification
of the cell lineage at the origin of basal cell carcinoma. Nat
Cell Biol. 2010;12(3):299e305.
59. Fan Q, Gu D, He M, et al. Tumor shrinkage by cyclopamine
tartrate through inhibiting hedgehog signaling. Chin J Canc.
2011;30(7):472e481.
60. Chen B, Trang V, Lee A, et al. Posaconazole, a second-
generation triazole antifungal drug, inhibits the hedgehog
signaling pathway and progression of basal cell carcinoma. Mol
Cancer Ther. 2016;15(5):866e876.
61. Fontenete S, Perez-Moreno M. Isolation of cancer stem cells
from squamous cell carcinoma. Methods Mol Biol. 2019;1879:
407e414.
62. Lowry WE, Flores A, White AC. Exploiting mouse models to
study ras-induced cutaneous squamous cell carcinoma. J
Investig Dermatol. 2016;136(8):1543e1548.
63. Malkoski SP, Haeger SM, Cleaver TG, et al. Loss of transforming
growth factor beta type II receptor increases aggressive tumor
behavior and reduces survival in lung adenocarcinoma and
squamous cell carcinoma. Clin Cancer Res. 2012;18(8):
2173e2183.
64. Schwarz M, Munzel PA, Braeuning A. Non-melanoma skin can-
cer in mouse and man. Arch Toxicol. 2013;87(5):783e798.
65. Huang PY, Balmain A. Modeling cutaneous squamous carcinoma
development in the mouse. Cold Spring Harb Perspect Med.
2014;4(9):a013623.
66. Schober M, Fuchs E. Tumor-initiating stem cells of squamous
cell carcinomas and their control by TGF-beta and integ-
rin/focal adhesion kinase (FAK) signaling. Proc Natl Acad Sci
USA. 2011;108(26):10544e10549.
67. Owens DM, Watt FM. Contribution of stem cells and differen-
tiated cells to epidermal tumours. Nat Rev Cancer. 2003;3(6):
444e451.capes of cutaneous basal cell carcinomas and squamous cell car-
.004
12 J. Wan et al.
+ MODEL68. Genander M, Cook PJ, Ramskold D, et al. BMP signaling and its
pSMAD1/5 target genes differentially regulate hair follicle
stem cell lineages. Cell Stem Cell. 2014;15(5):619e633.
69. Jian Z, Strait A, Jimeno A, Wang XJ. Cancer stem cells in
squamous cell carcinoma. J Investig Dermatol. 2017;137(1):
31e37.
70. Erfani E, Roudi R, Rakhshan A, Sabet MN, Shariftabrizi A,
Madjd Z. Comparative expression analysis of putative cancer
stem cell markers CD44 and ALDH1A1 in various skin cancer
subtypes. Int J Biol Mark. 2016;31(1):e53ee61.Please cite this article as: Wan J et al., Distinct transcriptomic lands
cinomas, Genes & Diseases, https://doi.org/10.1016/j.gendis.2019.1071. Tijink BM, Buter J, de Bree R, et al. A phase I dose escalation
study with anti-CD44v6 bivatuzumab mertansine in patients
with incurable squamous cell carcinoma of the head and neck
or esophagus. Clin Cancer Res. 2006;12(20 Pt 1):6064e6072.
72. Huang PY, Kandyba E, Jabouille A, et al. Lgr6 is a stem cell
marker in mouse skin squamous cell carcinoma. Nat Genet.
2017;49(11):1624e1632.
73. Suzuki K, Yamaguchi Y, Villacorte M, et al. Embryonic hair
follicle fate change by augmented beta-catenin through Shh
and Bmp signaling. Development. 2009;136(3):367e372.capes of cutaneous basal cell carcinomas and squamous cell car-
.004
